XML 73 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 6 Months Ended
Oct. 30, 2023
Feb. 28, 2023
Jun. 30, 2024
Jun. 30, 2023
Jul. 19, 2024
Jul. 17, 2024
Jun. 28, 2024
Dec. 31, 2023
Commitments And Contingencies Disclosure [Line Items]                
CVR derivative liability     $ 4,839         $ 4,722
Purchase of property and equipment     1,687 $ 4,219        
Investment, Type [Extensible Enumeration]         Other Long-Term Investments [Member]   Other Long-Term Investments [Member]  
Maximum                
Commitments And Contingencies Disclosure [Line Items]                
Investment subscription amount             $ 4,200  
Percentage of equity interest             18.90%  
Subsequent Event                
Commitments And Contingencies Disclosure [Line Items]                
Payment of initial investment           $ 1,700    
Property and Equipment                
Commitments And Contingencies Disclosure [Line Items]                
Purchase of property and equipment     1,600          
Research and Development                
Commitments And Contingencies Disclosure [Line Items]                
Committed to allocate     $ 19,000          
Contingent Value Rights Agreement                
Commitments And Contingencies Disclosure [Line Items]                
Percentage of excess cash on dispositions net     100.00%          
Excess amount retained from net proceeds related to disposition of assets     $ 1,000          
Percentage of excess preapproved costs     100.00%          
Distribution to CVR holders from asset sale proceeds   $ 200            
Long-term CVR derivative liability   $ 4,500            
CVR derivative liability               $ 4,700
Contributions closing payable amount $ 1,100              
Remaining outstanding balance     $ 300          
F351 | Gyre Pharmaceuticals | Submission of the New Drug Application                
Commitments And Contingencies Disclosure [Line Items]                
Obligation to pay in exchange for the intellectual property rights     4,600          
F351 | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection                
Commitments And Contingencies Disclosure [Line Items]                
Obligation to pay in exchange for the intellectual property rights     1,200          
F351 | Gyre Pharmaceuticals | NMPA's Approval of the NDA                
Commitments And Contingencies Disclosure [Line Items]                
Obligation to pay in exchange for the intellectual property rights     $ 7,000